Arnaud Tiberghien
Head, Chemistry & Platform Technology Science Bicycle Therapeutics plc
Arnaud is a pragmatic drug hunter with over 20 years in the biopharmaceutical industry. Contributed to the growth of dynamic biotechnology companies (Spirogen), and to innovation in large pharmaceutical organizations (Medimmune, AstraZeneca). Medicinal chemist with 40 publications / patents. Specialized in targeting modalities such as ADCs and PDCs. Major contributor to the development of the FDA approved ADC Zynlonta®. Currently Head of Chemistry in the Platform, Technology and Science (PTS) department at Bicycle Therapeutics. The role involves developing Peptides and Organic Chemistry teams to support Hit to Lead Discovery.
Seminars
Wednesday 25th February 2026
Leveraging Bicycle® Molecules as Radio-Imaging & Theranostics Agents
11:30 am
- Understanding Bicycle® Molecules: Contrasting discovery and PK/PD profiles compared to ADCs
- Assessing commonly used imaging techniques and understanding links to PK profiles
- Delving into Gallium-68 PET imaging with Bicycle® Molecules as predictors of target engagement
